IS2599B - 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess - Google Patents

3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Info

Publication number: IS2599B
Authority: IS; Iceland
Prior art keywords: phenylsulfonyl; piperazin; quinoline; pharmaceutically acceptable; acceptable derivatives
Prior art date: 2002-03-27

Application number

IS7470A

Other languages

English (en)

Other versions

IS7470A (is

Inventor

Mahmood Ahmed

Christopher Norbert Johnson

Martin C Jones

Gregor James Macdonald

Stephen Frederick Moss

Mervyn Thompson

Charles Edward Wade

David Witty

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-27

Filing date

2004-09-24

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2599(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from GB0207289A external-priority patent/GB0207289D0/en

2002-11-04 Priority claimed from GB0225678A external-priority patent/GB0225678D0/en

2004-09-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-09-24 Publication of IS7470A publication Critical patent/IS7470A/is

2010-04-15 Publication of IS2599B publication Critical patent/IS2599B/is

Links

JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS7470A 2002-03-27 2004-09-24 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess IS2599B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207289A GB0207289D0 (en)	2002-03-27	2002-03-27	Novel compounds
GB0225678A GB0225678D0 (en)	2002-11-04	2002-11-04	Novel compounds
PCT/EP2003/003197 WO2003080580A2 (en)	2002-03-27	2003-03-25	Quinoline derivatives and their use as 5-ht6 ligands

Publications (2)

Publication Number	Publication Date
IS7470A IS7470A (is)	2004-09-24
IS2599B true IS2599B (is)	2010-04-15

Family

ID=28456035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7470A IS2599B (is)	2002-03-27	2004-09-24	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess

Country Status (27)

Country	Link
US (5)	US7452888B2 (is)
EP (2)	EP1956004B1 (is)
JP (2)	JP4455064B2 (is)
KR (1)	KR101020399B1 (is)
CN (1)	CN1315809C (is)
AR (1)	AR039127A1 (is)
AT (1)	ATE398108T1 (is)
AU (1)	AU2003219103B2 (is)
BR (1)	BRPI0308696B8 (is)
CA (1)	CA2479786C (is)
CY (2)	CY1108313T1 (is)
DE (1)	DE60321558D1 (is)
DK (2)	DK1497266T3 (is)
ES (2)	ES2307919T3 (is)
IL (2)	IL164108A0 (is)
IS (1)	IS2599B (is)
MX (1)	MXPA04009318A (is)
MY (1)	MY138836A (is)
NO (1)	NO329319B1 (is)
NZ (1)	NZ535239A (is)
PL (1)	PL209872B1 (is)
PT (2)	PT1956004E (is)
RU (1)	RU2309154C9 (is)
SI (2)	SI1497266T1 (is)
TW (1)	TWI268928B (is)
WO (1)	WO2003080580A2 (is)
ZA (1)	ZA200407320B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2309154C9 (ru) *	2002-03-27	2016-09-27	Глэксо Груп Лимитед	3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
EP1592683A2 (en)	2003-02-14	2005-11-09	Wyeth	Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
WO2004074286A1 (en)	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE602004000260T2 (de)	2003-07-22	2006-08-24	Arena Pharmaceuticals, Inc., San Diego	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0320320D0 (en) *	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en) *	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en) *	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en) *	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en) *	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0425548D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	Radiolabelled ligands
GB0426313D0 (en) *	2004-12-01	2005-01-05	Merck Sharp & Dohme	Therapeutic agents
MX2007014929A (es)	2005-06-02	2008-02-15	Hoffmann La Roche	3-metansulfonilquinolinas como mejoradores de gaba-b.
AU2006286654A1 (en)	2005-07-27	2007-03-08	F. Hoffmann-La Roche Ag	4-aryloxy quinoline derivatives as 5-HT6 modulators
GB0519758D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519765D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en) *	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
US20090270371A1 (en) *	2005-12-20	2009-10-29	Gyorgy Keseru	Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
JP2009532471A (ja)	2006-04-05	2009-09-10	ワイス	５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体
MX2009006077A (es)	2007-01-08	2009-06-17	Suven Life Sciences Ltd	Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
CA2681162C (en) *	2007-03-15	2015-11-24	Novartis Ag	Benzyl and pyridine derivatives as modulators of hedgehog pathway
US20100041672A1 (en) *	2007-03-21	2010-02-18	Glaxo Group Limited	Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
UA97837C2 (ru)	2007-03-23	2012-03-26	Эбботт Гмбх Унд Ко. Кг	Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6
EA016594B1 (ru)	2007-05-03	2012-06-29	Сувен Лайф Сайенсиз Лимитед	Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов
MY146992A (en) *	2007-06-18	2012-10-15	Richter Gedeon Nyrt	Sulfonyl-quinoline derivatives
RU2483068C2 (ru) *	2007-08-07	2013-05-27	Эбботт Гмбх Унд Ко.Кг	Соединения хинолина, пригодные для лечения нарушений, являющихся ответом на модуляцию рецептора 5-ht6 серотонина
US7964627B2 (en)	2007-10-26	2011-06-21	Suven Life Sciences Limited	Amino arylsulfonamide compounds and their use as 5-HT6 ligands
EP2508177A1 (en)	2007-12-12	2012-10-10	Glaxo Group Limited	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
BRPI0908807A2 (pt) *	2008-02-15	2015-07-28	Hoffmann La Roche	Derivados de 3-alquil-piperazina e usos dos mesmos
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en)	2008-07-18	2010-02-18	Novartis Ag	Organic Compounds as Smo Inhibitors
US8318725B2 (en)	2008-09-17	2012-11-27	Suven Life Sciences Limited	Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
CA2737282C (en)	2008-09-17	2014-03-25	Suven Life Sciences Limited	Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TWI598337B (zh) *	2009-06-29	2017-09-11	阿吉歐斯製藥公司	治療化合物及組成物
BR112012016111B1 (pt) *	2010-01-04	2017-06-13	Nippon Soda Co	composto heterocíclico contendo nitrogênio, e, fungicida agrícola
JP5628937B2 (ja)	2010-01-05	2014-11-19	スベンライフサイエンシズリミティド	５−ｈｔ６受容体リガンドとしてのスルホン化合物
RU2443697C1 (ru) *	2010-12-21	2012-02-27	Александр Васильевич Иващенко	Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) *	2011-01-24	2013-04-03	이화여자대학교 산학협력단	5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es)	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
WO2013055386A2 (en)	2011-10-03	2013-04-18	The University Of Utah Research Foundation	Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) *	2012-10-25	2013-12-10	Андрей Александрович Иващенко	(3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
RU2642466C2 (ru)	2013-04-02	2018-01-25	Аннцзи Фармасьютикал Ко., Лтд.	Многофункциональные производные хинолина в качестве антинейродегенеративных агентов
US9302992B2 (en)	2013-04-02	2016-04-05	Annji Pharmaceutical Co., Ltd.	Multifunctional quinoline derivatives as anti-neurodegenerative agents
JP2018515607A (ja) *	2015-05-07	2018-06-14	アクソファントサイエンシーズゲーエムベーハーＡｘｏｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	神経変性疾患を処置する組成物および方法
US10022355B2 (en)	2015-06-12	2018-07-17	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt)	2015-07-15	2018-09-04	Axovant Sciences Gmbh	resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
AR106515A1 (es) *	2015-10-29	2018-01-24	Bayer Cropscience Ag	Sililfenoxiheterociclos trisustituidos y análogos
CN109069450A (zh) *	2016-02-05	2018-12-21	法奈克斯公司	神经障碍的新的组合疗法
WO2017157929A1 (en) *	2016-03-14	2017-09-21	AbbVie Deutschland GmbH & Co. KG	Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2017202206A1 (zh) *	2016-05-27	2017-11-30	深圳市塔吉瑞生物医药有限公司	一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) *	2016-12-02	2018-06-07	Axovant Sciences Gmbh	Methods for treating neurodegenerative disease
KR20210076224A (ko)	2019-12-13	2021-06-24	주식회사 에피바이오텍	퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) *	2020-12-09	2021-07-30	메디케어제약 주식회사	피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US708469A (en) *	1901-08-27	1902-09-02	George Lafayette Caldwell	Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja)	1988-12-08	1990-10-25	Japan Synthetic Rubber Co Ltd	有機非線形光学素子
SI9200377A (en) *	1992-12-11	1994-06-30	Krka	Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en)	1993-01-06	1993-03-03	Minnesota Mining & Mfg	Photothermographic materials
GB9311790D0 (en)	1993-06-08	1993-07-28	Minnesota Mining & Mfg	Photothermographic materials
US5596001A (en) *	1993-10-25	1997-01-21	Pfizer Inc.	4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
US5576338A (en) *	1995-02-15	1996-11-19	Merck Frosst Canada, Inc.	Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en)	1996-03-05	1996-03-28	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2750988B1 (fr)	1996-07-11	1998-09-18	Adir	Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en) *	1996-12-19	2001-12-13	Smithkline Beecham P.L.C.	Novel compounds
DZ2376A1 (fr)	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE59803962D1 (de)	1997-03-25	2002-06-06	Ciba Sc Holding Ag	Polycyclische Verbindungen
DE69818248T2 (de)	1997-04-22	2004-06-17	Janssen Pharmaceutica N.V.	Chinolin- und chinazolin-derivate als crf antagonisten
SI0991628T1 (en)	1997-05-28	2005-06-30	Aventis Pharmaceuticals Inc	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6376670B1 (en) *	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en)	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
US6172084B1 (en) *	1997-06-19	2001-01-09	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
EP0994862B1 (en)	1997-07-11	2005-06-01	SmithKline Beecham plc	Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
EP0930302B1 (en) *	1998-01-16	2003-04-02	F.Hoffmann-La Roche Ag	Benzosulfone derivatives
GB9801392D0 (en) *	1998-01-22	1998-03-18	Smithkline Beecham Plc	Novel compounds
GB9803411D0 (en)	1998-02-18	1998-04-15	Smithkline Beecham Plc	Novel compounds
US6100291A (en)	1998-03-16	2000-08-08	Allelix Biopharmaceuticals Inc.	Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) *	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en)	1998-08-28	1998-10-21	Smithkline Beecham Plc	Use
GB9819382D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds I
GB9820113D0 (en)	1998-09-15	1998-11-11	Merck Sharp & Dohme	Therapeutic agents
US6403808B1 (en) *	1999-12-10	2002-06-11	Virginia Commonwealth University	Selective 5-HT6 receptor ligands
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
AU4038000A (en)	1999-03-29	2000-10-16	Neurogen Corporation	4-substituted quinoline derivatives as gaba receptor ligands
ATE375990T1 (de)	1999-04-21	2007-11-15	Nps Allelix Corp	Piperidin-indol derivate mit 5-ht6 affinität
WO2000064877A1 (en)	1999-04-26	2000-11-02	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)	1999-09-07	2006-09-29	Upjohn Co	Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001032660A1 (en)	1999-11-05	2001-05-10	Nps Allelix Corp.	Compounds having 5-ht6 receptor antagonist activity
GB9926302D0 (en)	1999-11-05	2000-01-12	Smithkline Beecham Plc	Novel compounds
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) *	2000-03-28	2001-10-30	Neurogen Corporation	4-substituted quinoline derivatives
PE20020063A1 (es)	2000-06-20	2002-01-30	Upjohn Co	Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv)	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)	2000-08-31	2000-10-18	Smithkline Beecham Plc	Novel compounds
US6576644B2 (en)	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
CZ20031145A3 (cs)	2000-10-02	2003-12-17	Janssen Pharmaceutica N.V.	Antagonisté metabotropního glutamátového receptoru
KR100823908B1 (ko)	2000-10-20	2008-04-21	바이오비트럼 에이비(피유비엘)	2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
JP4184077B2 (ja)	2000-11-02	2008-11-19	ワイス	５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
US6849644B2 (en)	2000-11-21	2005-02-01	Smithkline Beecham P.L.C.	Isoquinoline derivatives useful in the treatment of CNS disorders
WO2002041889A2 (en)	2000-11-24	2002-05-30	Smithkline Beecham P.L.C.	Indolsulfonyl compounds useful in the treatment of cns disorders
ES2188344B1 (es)	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en)	2001-05-08	2001-06-27	Smithkline Beecham Plc	Novel compounds
BR0210929A (pt)	2001-06-07	2004-06-08	Hoffmann La Roche	Derivados de indol com afinidade para o receptor 5-ht6
ES2268113T3 (es)	2001-06-15	2007-03-16	F. Hoffmann-La Roche Ag	Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
ITRM20010356A1 (it) *	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
BR0211561A (pt)	2001-08-03	2004-11-30	Upjohn Co	Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos
EP1414442A1 (en)	2001-08-07	2004-05-06	Smithkline Beecham Plc	3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
MXPA04001250A (es)	2001-08-10	2004-05-27	Hoffmann La Roche	Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
JP2005504783A (ja)	2001-08-31	2005-02-17	ノバルティスアクチエンゲゼルシャフト	イロペリドン代謝産物の光学異性体
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
JP2005518414A (ja)	2001-12-21	2005-06-23	スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー	ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
AU2003244452A1 (en)	2002-02-05	2003-09-02	Glaxo Group Limited	Method of promoting neuronal growth
ATE323680T1 (de) *	2002-02-13	2006-05-15	Glaxo Group Ltd	7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
DE10207844A1 (de)	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US20030220325A1 (en)	2002-02-22	2003-11-27	Tenbrink Ruth E.	Arylsulfone derivatives
RU2309154C9 (ru) *	2002-03-27	2016-09-27	Глэксо Груп Лимитед	3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
WO2003080608A2 (en)	2002-03-27	2003-10-02	Glaxo Group Limited	Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
PT1506179E (pt)	2002-05-13	2006-06-30	Hoffmann La Roche	Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes
DE10221183A1 (de)	2002-05-13	2003-12-04	Max Planck Gesellschaft	Phosphatidyl-oligo-glycerine und Strukturanaloga
CA2485725A1 (en)	2002-06-05	2003-12-18	F. Hoffmann-La Roche Ag	1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
WO2004000828A1 (en)	2002-06-20	2003-12-31	Biovitrum Ab	New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
JP4754821B2 (ja) *	2002-06-20	2011-08-24	プロキシマゲン・リミテッド	肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
DK1587788T3 (da)	2002-09-17	2007-09-24	Hoffmann La Roche	2,7-substituerede indoler og anvendelsen deraf som 5-HT6-modulatorer
EP1542973B1 (en)	2002-09-17	2008-07-30	F. Hoffmann-La Roche Ag	2,4-substituted indoles and their use as 5-ht6 modulators
RU2324693C2 (ru)	2002-10-18	2008-05-20	Ф.Хоффманн-Ля Рош Аг	4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6
PL377770A1 (pl)	2002-11-08	2006-02-20	F. Hoffmann-La Roche Ag	Podstawione benzoksazynony i ich zastosowanie
WO2004050085A1 (en) *	2002-12-03	2004-06-17	F. Hoffmann-La Roche Ag	Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
WO2004074286A1 (en) *	2003-02-14	2004-09-02	Wyeth	Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR100751604B1 (ko)	2003-03-03	2007-08-22	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린
GB0305575D0 (en) *	2003-03-11	2003-04-16	Glaxo Group Ltd	Novel compounds
TWI289141B (en)	2003-03-11	2007-11-01	Hoffmann La Roche F. Ag.	Quinolinone derivatives and uses thereof
GB0320320D0 (en)	2003-08-29	2003-10-01	Glaxo Group Ltd	Novel compounds
GB0321473D0 (en)	2003-09-12	2003-10-15	Glaxo Group Ltd	Novel compounds
GB0322510D0 (en)	2003-09-25	2003-10-29	Glaxo Group Ltd	Novel compounds
GB0322629D0 (en)	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
GB0407025D0 (en)	2004-03-29	2004-04-28	Glaxo Group Ltd	Novel compounds
GB0411421D0 (en)	2004-05-21	2004-06-23	Glaxo Group Ltd	Novel compounds
GB0422263D0 (en)	2004-10-07	2004-11-10	Glaxo Group Ltd	Novel compounds
GB0519760D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds
GB0519758D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel process
GB0519765D0 (en)	2005-09-28	2005-11-09	Glaxo Group Ltd	Novel compounds

2003
- 2003-03-25 RU RU2004131641/04A patent/RU2309154C9/ru not_active IP Right Cessation
- 2003-03-25 WO PCT/EP2003/003197 patent/WO2003080580A2/en not_active Ceased
- 2003-03-25 CN CNB038116448A patent/CN1315809C/zh not_active Expired - Fee Related
- 2003-03-25 KR KR1020047015297A patent/KR101020399B1/ko not_active Expired - Fee Related
- 2003-03-25 PT PT08157490T patent/PT1956004E/pt unknown
- 2003-03-25 BR BRPI0308696A patent/BRPI0308696B8/pt not_active IP Right Cessation
- 2003-03-25 JP JP2003578335A patent/JP4455064B2/ja not_active Expired - Fee Related
- 2003-03-25 US US10/509,078 patent/US7452888B2/en not_active Expired - Lifetime
- 2003-03-25 AT AT03714889T patent/ATE398108T1/de active
- 2003-03-25 DE DE60321558T patent/DE60321558D1/de not_active Expired - Lifetime
- 2003-03-25 CA CA2479786A patent/CA2479786C/en not_active Expired - Fee Related
- 2003-03-25 AU AU2003219103A patent/AU2003219103B2/en not_active Ceased
- 2003-03-25 DK DK03714889T patent/DK1497266T3/da active
- 2003-03-25 PL PL374378A patent/PL209872B1/pl unknown
- 2003-03-25 DK DK08157490.7T patent/DK1956004T3/da active
- 2003-03-25 IL IL16410803A patent/IL164108A0/xx unknown
- 2003-03-25 ES ES03714889T patent/ES2307919T3/es not_active Expired - Lifetime
- 2003-03-25 EP EP08157490A patent/EP1956004B1/en not_active Expired - Lifetime
- 2003-03-25 TW TW092106558A patent/TWI268928B/zh not_active IP Right Cessation
- 2003-03-25 ES ES08157490T patent/ES2386828T3/es not_active Expired - Lifetime
- 2003-03-25 AR ARP030101028A patent/AR039127A1/es not_active Application Discontinuation
- 2003-03-25 PT PT03714889T patent/PT1497266E/pt unknown
- 2003-03-25 SI SI200331326T patent/SI1497266T1/sl unknown
- 2003-03-25 SI SI200332178T patent/SI1956004T1/sl unknown
- 2003-03-25 EP EP03714889A patent/EP1497266B1/en not_active Expired - Lifetime
- 2003-03-25 MX MXPA04009318A patent/MXPA04009318A/es active IP Right Grant
- 2003-03-25 MY MYPI20031054A patent/MY138836A/en unknown
- 2003-03-25 NZ NZ535239A patent/NZ535239A/en not_active IP Right Cessation
2004
- 2004-09-13 ZA ZA2004/07320A patent/ZA200407320B/en unknown
- 2004-09-14 IL IL164108A patent/IL164108A/en not_active IP Right Cessation
- 2004-09-24 IS IS7470A patent/IS2599B/is unknown
- 2004-10-25 NO NO20044588A patent/NO329319B1/no not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100943T patent/CY1108313T1/el unknown
- 2008-09-05 US US12/205,079 patent/US7601837B2/en not_active Expired - Fee Related
2009
- 2009-05-25 JP JP2009125459A patent/JP5091913B2/ja not_active Expired - Fee Related
- 2009-08-14 US US12/541,456 patent/US7799774B2/en not_active Expired - Fee Related
2010
- 2010-07-30 US US12/847,039 patent/US7977337B2/en not_active Expired - Fee Related
2011
- 2011-06-03 US US13/152,356 patent/US8236947B2/en not_active Expired - Fee Related
2012
- 2012-09-05 CY CY20121100804T patent/CY1113306T1/el unknown

Also Published As

Publication number	Publication date
BRPI0308696B1 (pt)	2019-07-16
CY1113306T1 (el)	2016-04-13
IL164108A (en)	2010-05-31
PL374378A1 (en)	2005-10-17
WO2003080580A3 (en)	2004-02-05
KR101020399B1 (ko)	2011-03-08
BRPI0308696B8 (pt)	2021-05-25
US20050124628A1 (en)	2005-06-09
RU2004131641A (ru)	2005-06-27
EP1497266B1 (en)	2008-06-11
DK1956004T3 (da)	2012-08-06
CN1656075A (zh)	2005-08-17
NO20044588L (no)	2004-10-25
KR20040094874A (ko)	2004-11-10
MXPA04009318A (es)	2005-01-25
AU2003219103B2 (en)	2008-10-23
TWI268928B (en)	2006-12-21
JP4455064B2 (ja)	2010-04-21
JP2009235080A (ja)	2009-10-15
EP1956004B1 (en)	2012-06-13
ATE398108T1 (de)	2008-07-15
US7601837B2 (en)	2009-10-13
IS7470A (is)	2004-09-24
EP1956004A1 (en)	2008-08-13
US20100305107A1 (en)	2010-12-02
JP5091913B2 (ja)	2012-12-05
PT1956004E (pt)	2012-08-31
AR039127A1 (es)	2005-02-09
BRPI0308696A8 (pt)	2017-04-11
NZ535239A (en)	2008-03-28
IL164108A0 (en)	2005-12-18
JP2005531518A (ja)	2005-10-20
MY138836A (en)	2009-07-31
US7452888B2 (en)	2008-11-18
US7977337B2 (en)	2011-07-12
ES2386828T3 (es)	2012-08-31
ES2307919T3 (es)	2008-12-01
RU2309154C9 (ru)	2016-09-27
ZA200407320B (en)	2005-11-30
SI1956004T1 (sl)	2012-09-28
BR0308696A (pt)	2005-01-25
RU2309154C2 (ru)	2007-10-27
PL209872B1 (pl)	2011-10-31
US20090036682A1 (en)	2009-02-05
NO329319B1 (no)	2010-09-27
SI1497266T1 (sl)	2008-10-31
PT1497266E (pt)	2008-09-10
US7799774B2 (en)	2010-09-21
DE60321558D1 (de)	2008-07-24
CY1108313T1 (el)	2014-02-12
HK1074439A1 (en)	2005-11-11
DK1497266T3 (da)	2008-10-06
US20090298841A1 (en)	2009-12-03
EP1497266A2 (en)	2005-01-19
US8236947B2 (en)	2012-08-07
US20110237792A1 (en)	2011-09-29
TW200403224A (en)	2004-03-01
AU2003219103A1 (en)	2003-10-08
CA2479786A1 (en)	2003-10-02
CA2479786C (en)	2011-11-29
WO2003080580A2 (en)	2003-10-02
CN1315809C (zh)	2007-05-16

Publication	Publication Date	Title
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
NO2022041I1 (no)	2022-10-03	Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC
IS2504B (is)	2009-04-15	Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
LUC00127I1 (fr)	2019-09-19	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
NO20041975L (no)	2005-07-16	Bicyklisk oksopyridin og oksopyrimidinderivater
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
ATE390426T1 (de)	2008-04-15	Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
ATE460418T1 (de)	2010-03-15	Heterocyclocarboxamidderivate
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK1474408T3 (da)	2012-06-25	N-Phenyl-2-pyrimidinaminderivater
IS6934A (is)	2003-08-29	Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
DK1513836T3 (da)	2006-09-11	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
DK1392670T3 (da)	2005-08-08	Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater